Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-06-27
2006-06-27
Murphy, Joseph (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000, C530S397000
Reexamination Certificate
active
07067477
ABSTRACT:
One aspect of the present invention is an isolated nucleic acid molecule encoding canine erythropoietin. The present invention also relates to an isolated canine erythropoietin protein or polypeptide. Another aspect of the present invention is a method for providing erythropoietin therapy to a dog or a cat including administering recombinant canine erythropoietin to a dog or a cat in need of erythropoietin therapy in an amount sufficient to increase production of reticulocytes and red blood cells in the dog or cat.
REFERENCES:
patent: 3865801 (1975-02-01), Chiba et al.
patent: 4558006 (1985-12-01), Egrie
patent: 4677195 (1987-06-01), Hewick et al.
patent: 4703008 (1987-10-01), Lin
patent: 4732889 (1988-03-01), Cynshi et al.
patent: 4835260 (1989-05-01), Shoemaker
patent: 5089397 (1992-02-01), Kushner et al.
patent: 5219739 (1993-06-01), Tischer et al.
patent: 5354934 (1994-10-01), Pitt et al.
patent: 5441868 (1995-08-01), Lin
patent: 5457089 (1995-10-01), Fibi et al.
patent: 5547933 (1996-08-01), Lin
patent: 5595900 (1997-01-01), Lowe
patent: 5597562 (1997-01-01), Nomura et al.
patent: 5621080 (1997-04-01), Lin
patent: 5661125 (1997-08-01), Strickland
patent: 5756349 (1998-05-01), Lin
patent: 5856298 (1999-01-01), Strickland
patent: 5955422 (1999-09-01), Lin
patent: 6696411 (2004-02-01), MacLeod
patent: 409-113 (1991-01-01), None
patent: 1 013 288 (2002-01-01), None
patent: WO 91/05867 (1991-05-01), None
patent: WO 94/02611 (1994-02-01), None
MacLeod et al., “Expression and Bioactivity of Recombinant Canine Erythropoietin,”Am J. Vet. Res.59(9):1144-1148 (1998).
Cowgill et el., “Use of Recombinant Human Erythropoietin for Management of Anemia in Dogs and Cats with Renal Failure,”J. Am. Vet. Med. Assoc.212(4):521-528 (1998).
Spivak, “Recombinant Human Erythropoietin and the Anemia of Cancer,”Blood84(4):997-1004 (1994).
Randolph et al., “Comparison of the Biological Activity and Safety of Recombinant Canine Erythropoietin to Recombinant Human Erythropoietin in Normal Beagle Dogs,” American College of Veterinary Internal Medicine, Official Abstract Form for Oral and Poster Presentation, 16thAnnual Veterinary Medical Forum (May 1998) (abstract).
Randolph et al., “Comaparison of the Biological Activity and Safety of Recombinant Canine Erythropoietin with that of Recombinant Human Erythropoietin in Clinically Normal Dogs,”Am. J. Vet. Res.60(5):636-642 (1999).
Wen et al., “Erythropoietin Structure-Function Relationships: High Degree of Sequence Homology Among Mammals,”Blood82:1507-1516 (1993).
Cornell Research Foundation Inc.
DeBerry Regina M.
Murphy Joseph
Nixon & Peabody LLP
LandOfFree
Canine erythropoietin gene and recombinant protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Canine erythropoietin gene and recombinant protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Canine erythropoietin gene and recombinant protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3634732